Key Takeaways Two phase 3 trials tested the same stem cell injection for complex Crohn’s perianal fistulas, separated by a decade. The first trial, ADMIRE-CD, showed a clear benefit and led to European approval in 2018. ADMIRE-CD II, a much larger follow-up trial, enrolled 568 patients and found no real
Key Takeaways Biologic therapies help many people with Crohn’s disease, but some patients stop responding over time or cannot tolerate them. Mesenchymal stem cells are the main type of stem cell treatments studied for Crohn’s, particularly for complex perianal fistulas. The only stem cell product ever approved for Crohn’s fistulas
Key Takeaways Stem cell treatment for ulcerative colitis targets the immune dysfunction at the root of the disease, not just the symptoms in the colon and rectum. Mesenchymal stem cells MSCs reduce harmful immune responses, expand regulatory T cells, and release growth factors that support mucosal healing and tissue regeneration.
Quick Summary Mesenchymal stem cell (MSC) therapy for IBD (Crohn’s disease and ulcerative colitis) reduces inflammation, supports repair of damaged intestinal tissue, and helps balance immune response. It is not a replacement for biologics or steroids but may work alongside them. Clinical trials show improved gut symptoms and mucosal healing
